IRIX logo

IRIDEX CORP

IRIXNASDAQ
๐Ÿ† #4976 by market capEarnings Nov 9US Equity
$0.64โ–ฒ $0.02 (+2.40%)
๐ŸŒ™ After hours$0.64โ–ฒ 0.00%Regular close ยท extended-hours price shown
๐Ÿ””
Track IRIX
Get earnings, price moves & breaking news on Telegram
Track
24hโ–ฒ 2.4%
7dโ–ผ 4.9%
14dโ–ฒ 0.1%
30dโ–ผ 10.9%
ytdโ–ผ 44.8%
1yโ–ผ 44.5%
๐ŸฆMarket Cap
$11M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
+8.2%
Slowing
๐Ÿ“ŠGross Margin
36.2%
Healthy
๐Ÿ’ตFCF Margin
-3.4%
Thin
โš–๏ธP/S Ratio
0.2x
Cheap
Otter Score
72
Fair

Trading Snapshot

Day Range
$0.63 โ€“ $0.65
52-Week Range
$0.61 โ€“ $1.65
Volume
$2.57B
Avg Volume
$3.38B
Shares Outstanding
17.3M
Next Earnings
Nov 5, 2026

Fundamentals Snapshot

Annual Revenue
$53M
Last Q Revenue
$13M
P/E Ratio
-3.1
P/S Ratio
0.2x
EPS (TTM)
$-0.20
Dividend Yield
0.00%
Dilution (1yr)
+2.2%

Why Investors Own IRIX

  • โœ“High-growth profile โ€” revenue up +47.3% YoY with expanding US Equity exposure.
  • โœ“Healthy economics โ€” 39% gross margin and 13% free-cash-flow margin.
  • โœ“New products and segments could unlock additional revenue streams.
โš ๏ธ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

IRIX logo

IRIDEX CORP

IRIX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$53Mโ–ฒ +8.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
36.7%โ–ผ โˆ’8.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnโ€™t profitable yet.
โˆ’$3Mโ–ผ โˆ’69.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
โˆ’$2Mโ–ผ โˆ’69.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerโ€™s slice.
17.4Mโ–ฒ +2.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$667Kโ–ผ โˆ’$121K YoY
StockOtter ยท stockotter.space

About IRIDEX CORP

IRIDEX Corporation is a medical technology firm specializing in ophthalmology. They develop and supply advanced therapeutic laser systems, various delivery instruments, and essential consumable tools designed to address vision-threatening ocular conditions. Their product portfolio includes several laser consoles, each tailored for specific eye conditions. The Cyclo G6 system is specifically engineered for glaucoma treatment. For ailments like diabetic macular edema and other retinal pathologies, IRIDEX provides the IQ 532 and IQ 577 laser photocoagulation systems. Furthermore, the OcuLight series, encompassing models such as TX, SL, SLx, GL, and GLx, offers solutions for managing severe retinal issues like proliferative diabetic retinopathy, macular holes, and retinal tears or detachments. Beyond laser consoles, the company also manufactures specialized delivery instruments. These include the TxCell scanning laser delivery system, which empowers clinicians with multi-spot pattern scanning capabilities. A unique slit lamp adapter enables practitioners to integrate standard slit lamps into their diagnostic and therapeutic workflows. Additionally, a laser indirect ophthalmoscope is available for interventions targeting peripheral retinal disorders. IRIDEX's offerings extend to various probes. The MicroPulse P3 Probe, when coupled with the Cyclo G6 laser system, facilitates MicroPulse transscleral laser therapy. For managing uncontrolled glaucoma, the G-Probe is employed, while both the G-Probe and G-Probe Illuminate are utilized in procedures addressing refractory glaucoma. The EndoProbe product line supports a range of vitrectomy procedures. Their diverse client base spans ophthalmology professionals, academic and research hospitals, government healthcare facilities, specialized surgical centers, general hospitals, veterinary clinics, and private medical practices. Product distribution is handled via an internal and independent sales network across the United States, supplemented by independent distributors for its international markets. Originally incorporated in 1989 as IRIS Medical Instruments, Inc., the company adopted the name IRIDEX Corporation in November 1995. Its corporate headquarters are situated in Mountain View, California.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)
๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿ’งDilutionโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Fair
72/100

Analyst Ratings

โ“˜
Consensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates